Download PDF
Thromb Haemost 1981; 46(04): 706-709
DOI: 10.1055/s-0038-1653457
Original Article
Schattauer GmbH Stuttgart

Fibrinopeptide A (FPA) Level and Fibrinogen Kinetics in Patients with Malignant Disease

Yasuhiro Yoda
The Division of Hematology, Institute of Clinical Medicine, The University of Tsukuba, Ibaraki, Japan
,
Tsukasa Abe
The Division of Hematology, Institute of Clinical Medicine, The University of Tsukuba, Ibaraki, Japan
› Author Affiliations
Further Information

Publication History

Received 30 January 1981

Accepted 24 September 1981

Publication Date:
05 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

FPA level, fibrinogen turnover rate, and fibrinolytic activity were studied on 18 patients with malignant disease. It was found that the FPA levels were significantly elevated and were correlated with fibrinogen turnover rate (r=0.74, p<0.001) and FDP (r = 0.58, p<0.02). Estimated FPA turnover rate was also correlated with fibrinogen turnover rate (r = 0.70, p<0.001). These results suggest that fibrinogen catabolism in patients with malignant disease is related with thrombin proteolysis. However, ratios of 1/2 FPA turnover rate to fibrinogen turnover rate suggest that intravascular thrombin proteolysis is not the major determinant of fibrinogen catabolism. It is suspected that extravascular thrombin proteolysis is responsible for the elevation of plasma FPA level which is correlated with acceleration of fibrinogen catabolism.

Keywords

Fibrinopeptide A - Fibrinogen kinetics - Malignant disease - Thrombin proteolysis
 

  • References

  • 1 Slichter SJ, Harker LA. Hemostasis in malignancy. Ann NY Acad Sei 1974; 230: 252-261
    CrossrefPubMedGoogle Scholar
  • 2 Lyman GH, Bettigole RE, Robson E, Ambrus JL, Urban H. Fibrinogen kinetics in patients with neoplastic disease. Cancer 1978; 41: 1113-1122
    CrossrefPubMedGoogle Scholar
  • 3 Peuscher FW, Cleton FJ, Armstrong L, Stoepman-Van DalenE, Van MeurikJ, Van AkenW. Significance of plasma fibrinopeptide A (fpA) in patients with malignancy. J Lab Clin Med 1980; 96: 5-14
    PubMedGoogle Scholar
  • 4 Sack GH Jr, Levin J, Bell WR. Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine 1977; 56: 1-37
    CrossrefPubMedGoogle Scholar
  • 5 Gordon SG. Cancer procoagulant A: a factor X activating precoagulant from malignant tissue. Thromb Res 1975; 6: 127-137
    CrossrefPubMedGoogle Scholar
  • 6 Pineo GF, Brain MC, Gallus AS, Hirsh J, Hatton MW, Regoecźi E. Tumors, mucus production, and hypercoagulability. Ann NY Acad Sri 1974; 230: 262-270
    PubMedGoogle Scholar
  • 7 Nossel HL, Yudelman I, Canfield RE, Butter VP Jr, Spanondis K, Wilner GD, Qureshi GD. Measurement of fibrinopeptide A in human blood. J Clin Invest 1974; 54: 43-53
    CrossrefPubMedGoogle Scholar
  • 8 Bradley J, Hickman JA. Behaviour of commercially prepared 125I- fibrinogen in metabolic studies. J Clin Path 1975; 28: 487-493
    CrossrefPubMedGoogle Scholar
  • 9 Garvey MB, Black JM. The detection of fibrinogen/fibrin degradation products by means of a new antibody-coated latex particle. J Clin Path 1972; 25: 680-682
    CrossrefPubMedGoogle Scholar
  • 10 Dacie JV, Lewis SM. Estimation of fibrinogen. In: Practical haematology 5. edition Livingstone: Churchill: 1975: 345-346
    Google Scholar
  • 11 Wilner GD, Chatpar P, Te A, Horowitz J. Effects of extravascular clotting on fibrinopeptide A levels in blood. J Lab Clin Med 1978; 91: 205-213
    PubMedGoogle Scholar